The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Junshi Biosciences enters distribution and marketing partnership with LEO Pharma for toripalimab in Europe: Shanghai, China Wednesday, January 22, 2025, 14:00 Hrs [IST] Shanghai J ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Junshi Biosciences and TopAlliance are set to enter a collaboration with LEO Pharma to distribute and market toripalimab in ...

China’s Junshi Biosciences yesterday revealed that its wholly-owned subsidiary TopAlliance Bioscience has entered into a ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

Shanghai-based Junshi Biosciences has announced a partnership with Denmark’s LEO Pharma to distribute and commercialise the ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

Under the agreement, LEO Pharma will be responsible for toripalimab's distribution, promotion, sales, etc., in up to 32 ...

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered ...